Vincerx Pharma Inc. has described drug conjugates comprising prodrugs of cyclin-dependent kinase 9 (CDK9) inhibitors covalently linked to an integrin binding moiety through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, cardiac hypertrophy and macular degeneration.